FDA Compliance Government Trials 
Drug & Device Law
JULY 26, 2023
2018), holding (as discussed here ) that New Jersey multi-county mass-tort litigation will henceforth be governed exclusively by New Jersey law, no matter where the plaintiff resided. That’s not likely to happen anymore because in 2018 the same court issued In re Accutane Litigation , 194 A.3d 3d 503, 523 (N.J. at 523-24. at *14-15. [I]n
Drug & Device Law
MARCH 19, 2024
Moreover, the defense prevailed in Hodges : The plaintiffs next argue that the trial justice erred in restricting the jury’s use of the evidence it introduced concerning certain government reports filed by [defendant] that detailed patients’ negative experiences after taking [the drug]. at 1228 (emphasis added).
Drug & Device Law
JANUARY 15, 2024
That is significant because, unlike (now) every other state in the country, since 1987 Pennsylvania precedent prohibited defendants from introducing evidence of their compliance with government and/or industry standards (“standards compliance” or “compliance” evidence, for short) in strict liability design defect cases – generally.
Expert insights. Personalized for you.
Let's personalize your content